{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T05:47:59Z","timestamp":1781416079604,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"DOI":"10.7759\/cureus.87453","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T16:30:05Z","timestamp":1751905805000},"source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive Review of the Ocular Toxicities Associated With Antibody-Drug Conjugates Used to Treat Gynecological Cancers"],"prefix":"10.7759","author":[{"given":"Jason","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhila","family":"Tetali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101705","article-title":"Antibody-antineoplastic conjugates in gynecological malignancies: current status and future perspectives","volume":"13","author":"Mart\u00edn-Sabroso C","year":"2021","unstructured":"Mart\u00edn-Sabroso C, Lozza I, Torres-Su\u00e1rez AI, Fraguas-S\u00e1nchez AI. Antibody-antineoplastic conjugates in gynecological malignancies: current status and future perspectives. Pharmaceutics. 2021, 13:1705. 10.3390\/pharmaceutics13101705","journal-title":"Pharmaceutics"},{"key":"ref2","unstructured":"Gynecologic cancer incidence, United States - 2012-2016, National Center for Chronic Disease Prevention and Health Promotion (U.S.). Division of Cancer Prevention and Control. (2019). https.\/\/stacks.cdc.gov\/view\/cdc\/81916."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102546","article-title":"The evolving landscape of antibody-drug conjugates in gynecologic cancers","volume":"116","author":"Tolcher A","year":"2023","unstructured":"Tolcher A, Hamilton E, Coleman RL. The evolving landscape of antibody-drug conjugates in gynecologic cancers. Cancer Treat Rev. 2023, 116:102546. 10.1016\/j.ctrv.2023.102546","journal-title":"Cancer Treat Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390772","article-title":"Antibody-drug conjugates in gynecologic cancer","volume":"43","author":"Karpel HC","year":"2023","unstructured":"Karpel HC, Powell SS, Pothuri B. Antibody-drug conjugates in gynecologic cancer. Am Soc Clin Oncol Educ Book. 2023, 43:e390772. 10.1200\/EDBK_390772","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20150089","article-title":"Antibody-drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters C","year":"2015","unstructured":"Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015, 35:e00225. 10.1042\/BSR20150089","journal-title":"Biosci Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-003701","article-title":"Integrating antibody drug conjugates in the management of gynecologic cancers","volume":"33","author":"Chelariu-Raicu A","year":"2023","unstructured":"Chelariu-Raicu A, Mahner S, Moore KN, Lorusso D, Coleman RL. Integrating antibody drug conjugates in the management of gynecologic cancers. Int J Gynecol Cancer. 2023, 33:420-9. 10.1136\/ijgc-2022-003701","journal-title":"Int J Gynecol Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu Y","year":"2023","unstructured":"Zhu Y, Liu K, Wang K, Zhu H. Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer. 2023, 129:283-95. 10.1002\/cncr.34507","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in human clinical trials","volume":"31","author":"Eaton JS","year":"2015","unstructured":"Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015, 31:589-604. 10.1089\/jop.2015.0064","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study","volume":"35","author":"Moore KN","year":"2017","unstructured":"Moore KN, Martin LP, O'Malley DM, et al.. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol. 2017, 35:1112-8. 10.1200\/JCO.2016.69.9538","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30736","article-title":"Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor \u03b1-targeting antibody-drug conjugate, in patients with solid tumors","volume":"123","author":"Moore KN","year":"2017","unstructured":"Moore KN, Borghaei H, O\u2019Malley DM, et al.. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor \u03b1-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017, 123:3080-7. 10.1002\/cncr.30736","journal-title":"Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"O'Malley DM","year":"2020","unstructured":"O'Malley DM, Matulonis UA, Birrer MJ, et al.. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020, 157:379-85. 10.1016\/j.ygyno.2020.01.037","journal-title":"Gynecol Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert L","year":"2023","unstructured":"Gilbert L, Oaknin A, Matulonis UA, et al.. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2023, 170:241-7. 10.1016\/j.ygyno.2023.01.020","journal-title":"Gynecol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman R","year":"2021","unstructured":"Coleman R, Lorusso D, Gennigens C, et al.. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021, 22:609-19. 10.1016\/S1470-2045(21)00056-5","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"de Bono JS","year":"2019","unstructured":"de Bono JS, Concin N, Hong DS, et al.. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 2019, 20:383-93. 10.1016\/S1470-2045(18)30859-3","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2474","article-title":"Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine","volume":"25","author":"Matulonis UA","year":"2019","unstructured":"Matulonis UA, Birrer MJ, O'Malley DM, et al.. Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine. Clin Cancer Res. 2019, 25:1727-36. 10.1158\/1078-0432.CCR-18-2474","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04337-8","article-title":"Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics","volume":"257","author":"Kunkler AL","year":"2019","unstructured":"Kunkler AL, Binkley EM, Mantopoulos D, et al.. Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. Graefes Arch Clin Exp Ophthalmol. 2019, 257:1771-81. 10.1007\/s00417-019-04337-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"Martin LP","year":"2017","unstructured":"Martin LP, Konner JA, Moore KN, et al.. Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017, 147:402-7. 10.1016\/j.ygyno.2017.08.015","journal-title":"Gynecol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.07.017","article-title":"Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer","volume":"151","author":"Moore KN","year":"2018","unstructured":"Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018, 151:46-52. 10.1016\/j.ygyno.2018.07.017","journal-title":"Gynecol Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221139775","article-title":"A review of the novel tissue factor antibody-drug conjugate: tisotumab vedotin","volume":"29","author":"Luu K","year":"2023","unstructured":"Luu K, Chu A, Chang B. A review of the novel tissue factor antibody-drug conjugate: tisotumab vedotin. J Oncol Pharm Pract. 2023, 29:441-9. 10.1177\/10781552221139775","journal-title":"J Oncol Pharm Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji U","year":"2019","unstructured":"Banerji U, Herpen C, Saura C, et al.. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019, 20:1124-35. 10.1016\/S1470-2045(19)30328-6","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0419-7","article-title":"First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors","volume":"35","author":"Shapiro GI","year":"2017","unstructured":"Shapiro GI, Vaishampayan UN, LoRusso P, et al.. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Invest New Drugs. 2017, 35:315-23. 10.1007\/s10637-016-0419-7","journal-title":"Invest New Drugs"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.09.023","article-title":"An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer","volume":"163","author":"Liu J","year":"2021","unstructured":"Liu J, Burris H, Wang JS, et al.. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2021, 163:473-80. 10.1016\/j.ygyno.2021.09.023","journal-title":"Gynecol Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial S","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, et al.. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020, 21:207-21. 10.1016\/S1470-2045(19)30788-0","journal-title":"Lancet Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0618","article-title":"FDA approval summary: belantamab mafodotin for patients with relapsed or refractory multiple myeloma","volume":"28","author":"Baines AC","year":"2022","unstructured":"Baines AC, Ershler R, Kanapuru B, et al.. FDA approval summary: belantamab mafodotin for patients with relapsed or refractory multiple myeloma. Clin Cancer Res. 2022, 28:4629-33. 10.1158\/1078-0432.CCR-22-0618","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00369-0","article-title":"Single-agent belantamab mafodotin for relapsed\/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study","volume":"10","author":"Richardson PG","year":"2020","unstructured":"Richardson PG, Lee HC, Abdallah AO, et al.. Single-agent belantamab mafodotin for relapsed\/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J. 2020, 10:106. 10.1038\/s41408-020-00369-0","journal-title":"Blood Cancer J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18479","article-title":"Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: A multicentre retrospective study","volume":"200","author":"Shragai T","year":"2023","unstructured":"Shragai T, Magen H, Lavi N, et al.. Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: A multicentre retrospective study. Br J Haematol. 2023, 200:45-53. 10.1111\/bjh.18479","journal-title":"Br J Haematol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01172-5","article-title":"Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report","volume":"14","author":"Marquant K","year":"2021","unstructured":"Marquant K, Quinquenel A, Arndt C, Denoyer A. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report. J Hematol Oncol. 2021, 14:159. 10.1186\/s13045-021-01172-5","journal-title":"J Hematol Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2409","article-title":"Exposure-response analyses for therapeutic dose selection of belantamab mafodotin in patients with relapsed\/refractory multiple myeloma","volume":"110","author":"Ferron-Brady G","year":"2021","unstructured":"Ferron-Brady G, Rathi C, Collins J, Struemper H, Opalinska J, Visser S, Jewell RC. Exposure-response analyses for therapeutic dose selection of belantamab mafodotin in patients with relapsed\/refractory multiple myeloma. Clin Pharmacol Ther. 2021, 110:1282-92. 10.1002\/cpt.2409","journal-title":"Clin Pharmacol Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000001805","article-title":"Ocular toxicity of mirvetuximab","volume":"38","author":"Corbelli E","year":"2019","unstructured":"Corbelli E, Miserocchi E, Marchese A, et al.. Ocular toxicity of mirvetuximab. Cornea. 2019, 38:229-32. 10.1097\/ICO.0000000000001805","journal-title":"Cornea"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/360933-comprehensive-review-of-the-ocular-toxicities-associated-with-antibody-drug-conjugates-used-to-treat-gynecological-cancers","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T16:30:06Z","timestamp":1751905806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/360933-comprehensive-review-of-the-ocular-toxicities-associated-with-antibody-drug-conjugates-used-to-treat-gynecological-cancers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.87453","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}